Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1000 participants.
Also called NCT04373707
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 1,000 participants
- Registry
-
NCT04373707
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT04373707. Randomized; single masking; primary purpose prevention. Start 2020-05-13 (actual); primary completion 2021-04-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
- Acronym
- COVI-DOSE
- Condition
- COVID
- Condition
- Thrombosis
- Condition
- Pulmonary Embolism
- Condition
- Deep Vein Thrombosis
- Intervention (Drug)
- Enoxaparin
- Intervention (Drug)
- Enoxaparin
- Lead sponsor
- Central Hospital, Nancy, France
- Collaborator
- Ministry of Health, France
- Collaborator
- Grand Est Region
- Collaborator
- University Hospital of Saint-Etienne
Record details
- Record id
cardio:ct-nct04373707- Content hash
76aabd02a723d0c3443782690867677f0fe548c00702dc87a8a49b58e947a0fc